President Obama Selects Chuck Rosenberg to Head Beleaguered U.S. Drug Enforcement Administration (DEA)
DEA Increasingly Scrutinized as States Legalize Marijuana and Public Opinion Turns Against Failed Drug War
Correction: A previous version of this press release referred to upcoming Senate confirmation hearings. Since this appointment is only for an “acting” DEA Administrator, however, it does not require Senate approval. An updated version of today’s press release is below.
A senior F.B.I. official and former U.S. attorney, Chuck Rosenberg, has been selected by President Obama as acting director of the Drug Enforcement Administration. Rosenberg has served as the chief of staff to the F.B.I. director, James B. Comey, for the past 18 months.
Outgoing DEA head Michele Leonhart announced her retirement last month in the wake of numerous scandals. She came under intense criticism for opposing the Obama administration’s efforts to reform mandatory minimum sentencing laws, and for opposing the administration’s hands-off approach in the four states that have approved legal regulation of marijuana.
The DEA has existed for more than 40 years but little attention has been given to the role the agency has played in fueling mass incarceration, racial disparities, the surveillance state, and other drug war problems. Congress has rarely scrutinized the agency, its actions or its budget, instead showing remarkable deference to the DEA’s administrators. That has started to change recently, and Leonhart’s departure was seen as an opportunity to appoint someone who will overhaul the agency and support reform.
“The new DEA chief has a tough job ahead,” said Bill Piper, director of national affairs for the Drug Policy Alliance. “Let’s hope he’s in line with the political consensus in favor of scaling back mass incarceration and the worst harms of the drug war.”The Drug Policy Alliance’s online campaign has raised awareness of the damage the DEA is causing, and the organization and its allies have been working with members of Congress to cut the agency’s budget and reduce its power.
Just today, DPA placed a mock “Help Wanted” ad in Capitol Hill newspaper Roll Call that highlights the major flaws with Leonhart’s regime – and that lays out all the problems that the next DEA administrator must try to avoid. The tongue-in-cheek ad sought a new head of the Drug Enforcement Administration (DEA) to “prolong the failed war on drugs,” with primary areas of job responsibility to include “Mass Incarceration,” “Police State Tactics,” “Obstruction of Science,” “Subverting Democracy” and “Undermining Human Rights.”
“Drug prohibition, like alcohol Prohibition, breeds crime, corruption, and violence – and creates a situation where law enforcement officers must risk their lives in a fight that can’t be won,” said Ethan Nadelmann, executive director of the Drug Policy Alliance. “It’s time to reform not just the DEA but broader U.S. and global drug policy. The optimal drug policy would reduce the role of criminalization and the criminal justice system in drug control to the greatest extent possible, while protecting public safety and health.”
DPA also recently released a new issue brief, The Scandal-Ridden DEA: Everything You Need to Know. The brief covers numerous DEA scandals, including the massacre of civilians in Honduras, the inappropriate use of NSA resources to spy on U.S. citizens and the use of fabricated evidence to cover it up, the warrantless tracking of billions of U.S. phone calls, and the misuse of confidential informants. The brief notes that the traditional U.S. drug policy goal of using undercover work, arrests, prosecutions, incarceration, interdiction and source-country eradication to try to make America "drug-free" has failed to substantially reduce drug use or drug-related harms. It instead has created problems of its own – broken families, increased poverty, racial disparities, wasted tax dollars, prison overcrowding and eroded civil liberties.
Even as U.S. states, Congress, and the Obama Administration move forward with marijuana legalization, sentencing reform, and other drug policy reforms, the DEA has fought hard to preserve the failed policies of the past. Last year, Leonhart publicly rebuked President Obama for saying that marijuana is as safe as alcohol, told members of Congress that the DEA will continue to go after marijuana even in states where it is legal despite DOJ guidance stating otherwise, and spoke out against bipartisan drug sentencing reform in Congress that the Obama administration is supporting.
The DEA also has a long history of obstructing scientific research and refusing to acknowledge established science, as chronicled in a report by DPA and MAPS last year, The DEA: Four Decades of Impeding and Rejecting Science. DEA administrators, including Leonhart, have on several occasions ignored research and overruled the DEA’s own administrative law judges on the medical uses of marijuana and MDMA.
In a recent report the Justice Department’s Office of Inspector General found that the DEA withheld information and obstructed investigations. In a hearing last week senators grilled the DEA for failing to provide information and answer basic questions. “It’s been now eight months — I still don’t have a response from DEA to these questions,” Senate Judiciary Chairman Chuck Grassley said. “When we don’t get responses to our letters, that colors our view of the agency — particularly when we’re writing about a constituent who suffered from a real lapse in process,” Senator Diane Feinstein said.
Last year Congress passed a spending limitation amendment prohibiting the DEA from undermining state marijuana laws. It was signed into law by President Obama, but expires later this year. The U.S. House also approved two amendments prohibiting the DEA from interfering with state hemp laws. An amendment to shift $5 million from the agency to a rape kit testing program passed overwhelmingly. Numerous hearings have already been held this year scrutinizing the agency. Reformers say more amendments, bills, and hearings are on the way.
For more background, including DPA’s reports, press releases, op-eds and news articles, see: drugpolicy.org/DEA
Tony Newman 646-335-5384
Bill Piper 202-669-6430